Lowering Serum Trough Concentration of Indinavir Reduces Toxicity -- HIV/AIDS INFO AND UPDATES

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 12:06:33 05/16/02 Thu
Author: Anonymous
Subject: Lowering Serum Trough Concentration of Indinavir Reduces Toxicity

http://www.medscape.com/viewarticle/432487_print
Lowering Serum Trough Concentration of Indinavir Reduces Toxicity

Reuters Health Information 2002. � 2002 Reuters Ltd
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are rehttp://www.medscape.com/viewarticle/432487_printgistered trademarks and trademarks of the Reuters group of companies around the world.
Introduction
NEW YORK (Reuters Health) Apr 23 - Maintaining serum trough concentration of the HIV protease inhibitor indinavir at <500 ng/mL appears to keep toxicity at manageable levels without affecting efficacy, French investigators report.

In a retrospective study of 63 HIV-infected patients being treated initially with indinavir-ritonavir 800/100 mg twice daily, the median indinavir trough concentration was 1465 ng/mL, ranging from 126 to 7779 ng/mL.

Dr. Caroline Solas, of the Timone Hospital in Marseille, and associates observed that 49 had an indinavir trough concentration >500 ng/mL, and 67% of them exhibited toxicity. The incidence of toxicity was 36% among those with lower trough concentration, the investigators report in the April 1st issue of the Journal of Acquired Immune Deficiency Syndromes.

Symptoms included cheilitis and dehydration of the skin, renal colic, elevated creatinemia, and gastrointestinal problems.

Dosage adjustments were made when necessary, after which measurements were repeated for 77 individuals. Median indinavir trough concentration was 459 ng/mL, peaking at 3199 ng/mL. Toxicity was reduced to 8%.

Adverse events persisted in 12 patients, five of whom discontinued indinavir and seven of whom achieved good tolerance after further dosage adjustment.

In the 92% of patients in whom viral levels were measured, "no statistical difference was observed between patients with an indinavir trough concentration <500 ng/mL and patients with an indinavir trough concentration >500 ng/mL."

Dr. Solas and her associates conclude, "An optimal concentration range for indinavir trough concentration could be 150 to 500 ng/mL for an indinavir-ritonavir twice daily regimen."

J Acquir Immune Defic Syndr 2002;29:374-377.

[ Next Thread | Previous Thread | Next Message | Previous Message ]